EBA, Safety and Tolerability of Sanfetrinem Cilexetil

  • End date
    Dec 1, 2023
  • participants needed
  • sponsor
    TASK Applied Science
Updated on 3 June 2022


To evaluate the 2-week bactericidal activity, pharmacokinetics, safety and tolerability of sanfetrinem cilexetil in participants with rifampicin-susceptible pulmonary tuberculosis.


A single-centre, open-label, clinical trial in two stages. Stage 1 will recruit 20 participants followed by a recruitment pause and an interim analysis to determine if sanfetrinem cilexetil has early bactericidal activity (EBA). Should EBA be demonstrated, stage 2 will focus on optimising sanfetrinem cilexetil.

All treatments will be administered orally (PO) on days 1-14. The treatments are:

Stage 1:

  • Sanfetrinem cilexetil 1.6 g PO 12-hourly
  • Rifampicin 35 mg/kg PO once daily (OD)*

An interim analysis is planned after stage 1 to review the pharmacokinetics (PK), safety, tolerability and EBA of sanfetrinem cilexetil. Results of stage 1 will determine whether stage 2 should proceed and if any modifications in dose, duration or combinations are required for Stage 2. If deemed possible, a PK-EBA model will be derived using only stage 1 from which clinical trial simulations will be conducted to inform the design of stage 2. If EBA is not demonstrated, the study will be stopped after stage 1.

Stage 2:

  • Rifampicin 35 mg/kg po OD*
  • Sanfetrinem cilexetil 3.2 g PO OD
  • Sanfetrinem cilexetil 800 mg PO 12-hourly
  • Sanfetrinem cilexetil 800 mg PO 8-hourly
  • Sanfetrinem cilexetil 1.6 g plus amoxicillin/clavulanic acid (Amx/CA) 250mg/125 mg, PO 12-hourly
  • Sanfetrinem cilexetil 1.6 g 12-hourly plus rifampicin 35 mg/kg PO OD
  • Five of the rifampicin 35 mg/kg arm participants will be recruited in stage 1 and the remainder in stage 2.

Participants on rifampicin will serve both as control for the EBA quantitative mycobacteriology and allow evaluation of pharmacodynamic-pharmacodynamic (PD-PD) interaction between rifampicin and sanfetrinem.

The study will not be blinded but the mycobacteriology laboratory staff performing the endpoint assays will remain blinded until analysis of the EBA results.

Condition Tuberculosis, Pulmonary
Treatment rifampicin, Amoxicillin/clavulanic acid, Sanfetrinem Cilexetil
Clinical Study IdentifierNCT05388448
SponsorTASK Applied Science
Last Modified on3 June 2022


Yes No Not Sure

Inclusion Criteria

Participants are required to meet all of the following criteria in order to be randomized
Provide written, informed consent prior to all trial-related procedures
Male or female, aged between 18 and 65 years, inclusive
Body weight (in light clothing and with no shoes) between 40 and 90 kg, inclusive
Newly diagnosed, previously untreated, rifampicin-susceptible pulmonary TB
A chest X-ray picture taken at screening which, in the opinion of the investigator, is consistent with TB
Sputum positive on direct microscopy for acid-fast bacilli on at least one sputum sample (at least 1+ on the IUATLD/WHO scale) or GeneXpert cycle threshold of medium or high
Ability to produce an adequate volume of sputum as estimated from an overnight sputum collection sample (estimated 10 ml or more)
Be of non-childbearing potential or using effective methods of birth control, as defined below
Non-childbearing potential
Female participant/ female sexual partner - bilateral oophorectomy
bilateral tubal ligation
postmenopausal with no menses for at least 12 consecutive months Male participant/ male sexual partner - vasectomy
bilateral orchidectomy more than three months prior to screening
Effective birth control methods
Participant is not heterosexually active or practicing sexual abstinence
Double barrier method which can include a male condom, diaphragm, cervical cap, or female condom (male and female condoms should not be used together); or
Barrier method combined with hormone-based contraceptives or an intra-uterine device for the female partner

Exclusion Criteria

Participants will be excluded from participation if they fulfil any of the following criteria
Evidence of clinically significant conditions or findings, other than TB, that might compromise safety or the interpretation of trial endpoints, per discretion of the investigator
Poor general condition where any delay in treatment cannot be tolerated per discretion of the investigator
Clinically significant evidence of extrathoracic TB, as judged by the investigator
History of allergy to any of the trial IP/s or related substances i.e. β-lactams and penicillin, as confirmed by the clinical judgement of the investigator
Alcohol or drug abuse, that in the opinion of the investigator, is sufficient to compromise the safety or cooperation of the participant
HIV positive ONLY IF
CD4 < 250cells/mm3
Participation in other clinical studies with investigational agents within 8
weeks prior to trial start (with the exception of COVID-19 vaccines)
Female participant who is pregnant, breast-feeding, or planning to conceive a child within the anticipated period of trial participation. Male participant planning to conceive a child within the anticipated period of participating in the trial
Treatment received with any drug active against M.tb (including but not limited to isoniazid, ethambutol, amikacin, cycloserine, fluoroquinolones, rifabutin, rifampicin, streptomycin, kanamycin, para-aminosalicylic acid, rifapentine, pyrazinamide, thioacetazone, capreomycin, thioamides), or with immunosuppressive medications such as TNF-alpha inhibitors within 2 weeks prior to screening, or systemic corticosteroids for more than 7 days within 2 weeks prior to screening
Participants with the following toxicities at screening as defined by the enhanced CTCEA toxicity table
creatinine >1.5 times upper limit of normal [ULN]
haemoglobin <8.0 g/dL
platelets <50x109 cells/L
serum potassium <3.0 mmol/L
aspartate aminotransferase (AST) ≥3.0 x ULN
alanine aminotransferase (ALT) ≥3.0 x ULN
Total white cell count <1.5 cells/L
For participants undergoing PET/CT, the following are excluded
Participants with diabetes (Type 1 or 2) with point of care HbA1c above 6.5, or random glucose over 11.1 mmol/L
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note